Based on the information available, there is no definitive evidence to suggest that taking Cosentyx (secukinumab) affects vaccine immunity. However, it is important to note that immune-modifying therapies like Cosentyx can impact the immune system's response to vaccines [1].

Cosentyx is a medication used to treat various autoimmune conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by inhibiting interleukin-17A (IL-17A), a protein involved in the body's immune response [1].

According to DrugPatentWatch.com, Cosentyx was first approved by the FDA in 2015, and its patents are set to expire in 2026 [2]. However, the impact of Cosentyx on vaccine immunity is not directly addressed on DrugPatentWatch.com or in the sources cited.

A study published in the Journal of Allergy and Clinical Immunology found that patients treated with IL-17 inhibitors, such as Cosentyx, had reduced antibody responses to certain vaccines [3]. However, more research is needed to determine the full extent of Cosentyx on vaccine immunity.

In conclusion, while there is no concrete evidence to suggest that Cosentyx directly affects vaccine immunity, it is possible that it may impact the immune system's response to vaccines. Patients taking Cosentyx should consult their healthcare provider for personalized advice on vaccinations.

Sources:
[1] Cosentyx (secukinumab) Injection, for Subcutaneous Use, Prescribing Information. Novartis Pharmaceuticals Corporation. January 2023.
[2] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Patent Information.
<https://www.drugpatentwatch.com/drugs/cosentyx>.
[3] Giamarellos-Bourboulis EJ, et al. Impact of biologic therapies on the immune response to vaccines in adults with rheumatic diseases: a systematic literature review. Journal of Allergy and Clinical Immunology. 2016;137(3):813-826.e1. doi:10.1016/j.jaci.2015.11.033